1
|
Goel R, Shah S, Sundar G, Arora R, Gupta S, Khullar T. Orbital and ocular perfusion in thyroid eye disease. Surv Ophthalmol 2023; 68:481-506. [PMID: 36681278 DOI: 10.1016/j.survophthal.2023.01.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2022] [Revised: 12/20/2022] [Accepted: 01/13/2023] [Indexed: 01/20/2023]
Abstract
Thyroid eye disease (TED) is characterized by enlargement of extraocular muscles, an increase in retrobulbar fat, orbital fibrosis, and fluctuations in plasma thyroid hormone levels in most patients, often associated with raised autoantibody titers. The occurrence of orbital space conflict compromises the orbital perfusion, unchecked progression of which results in irreversible loss of visual acuity and visual fields. The quantitative assessment of orbital perfusion can be done by measurement of blood flow velocities in the superior ophthalmic vein (SOV), ophthalmic artery (OA), central retinal artery (CRA), and posterior ciliary artery by color Doppler imaging. The retinal and choroidal microvasculature is studied by optical coherence tomography and optical coherence tomography angiography. The orbital and ocular perfusion fluctuates during the course of TED. Orbital congestion is reflected by the reduction or reversal of SOV flow and an increase in subfoveal choroidal thickness. The active phase is characterized by high blood flow velocities of the OA and CRA. The onset of dysthyroid optic neuropathy is associated with reduced arterial perfusion and reduction in parafoveal and peripapillary vascular density. Orbital decompression improves the SOV flow and decreases the resistivity index of CRA. Sequential evaluation of orbital hemodynamic changes can thus supplement the clinical scoring systems for monitoring and planning intervention in TED.
Collapse
Affiliation(s)
- Ruchi Goel
- Department of Ophthalmology, Maulana Azad Medical College, New Delhi, India.
| | - Shalin Shah
- Department of Ophthalmology, Maulana Azad Medical College, New Delhi, India
| | - Gangadhara Sundar
- Department of Ophthalmology, National University Hospital, Kent Ridge, Singapore
| | - Ritu Arora
- Department of Ophthalmology, Maulana Azad Medical College, New Delhi, India
| | - Swati Gupta
- Department of Radiology, Maulana Azad Medical College, New Delhi, India
| | - Tamanna Khullar
- Department of Radiology, Maulana Azad Medical College, New Delhi, India
| |
Collapse
|
2
|
Danielewska ME, Kicińska AK, Placek MM, Lewczuk K, Rękas M. Changes in spectral parameters of corneal pulse following canaloplasty. Graefes Arch Clin Exp Ophthalmol 2019; 257:2449-2459. [PMID: 31377849 DOI: 10.1007/s00417-019-04433-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2019] [Revised: 07/09/2019] [Accepted: 07/23/2019] [Indexed: 10/26/2022] Open
Abstract
PURPOSE To ascertain whether changes in the spectral content of the corneal pulse (CP) signal, measured in vivo in primary open-angle glaucoma (POAG) patients, indirectly reflect changes in corneal biomechanics after canaloplasty. METHODS Fifteen eyes of 15 POAG patients who underwent canaloplasty combined with phacoemulsification were enrolled. Standard ophthalmic examinations were conducted before washout, pre-operatively, at days 1, 7, and 1, 3, 6, and 12 months after surgery. Non-contact measurements of the CP signal were performed at pre-washout, pre-operatively, and at 3, 6, and 12 months post-operatively. Then, amplitudes of the CP first five harmonics associated with the heart rate were estimated. Temporal changes of all considered parameters were tested at a Bonferroni-adjusted significance level set to 0.005. RESULTS A decrease in the amplitude of the first harmonic and an increase in the normalized amplitude of the third harmonic (ACP3n) of the CP signal were noticed between the pre-washout and the pre-operative stages (p = 0.003 and p = 0.004, respectively). This corresponds to an increase in median intraocular pressure (IOP) values by 6.0 mmHg (p = 0.0045). After surgery, ACP3n reached the highest value at 3 months post-operatively, compared with pre-washout level (p = 0.0045). CONCLUSIONS Alterations in corneoscleral stiffness caused by surgery are reflected in changes in the ACP3n value. Hence, post-operative corneal biomechanics could be monitored indirectly by this supporting indicator that can be used to estimate the time at which measures of IOP are no longer biased by the changed cornea boundary conditions caused by canaloplasty. CLINICAL TRIALS REGISTRATION NCT02908633.
Collapse
Affiliation(s)
- Monika E Danielewska
- Department of Biomedical Engineering, Faculty of Fundamental Problems of Technology, Wrocław University of Science and Technology, Wybrzeże Wyspiańskiego 27, 50-370, Wrocław, Poland.
| | - Aleksandra K Kicińska
- Department of Ophthalmology, Military Institute of Medicine, ul. Szaserów 128, 04-141, Warsaw, Poland
| | - Michał M Placek
- Department of Biomedical Engineering, Faculty of Fundamental Problems of Technology, Wrocław University of Science and Technology, Wybrzeże Wyspiańskiego 27, 50-370, Wrocław, Poland
| | - Katarzyna Lewczuk
- Department of Ophthalmology, Military Institute of Medicine, ul. Szaserów 128, 04-141, Warsaw, Poland
| | - Marek Rękas
- Department of Ophthalmology, Military Institute of Medicine, ul. Szaserów 128, 04-141, Warsaw, Poland
| |
Collapse
|
3
|
Adeghate J, Rahmatnejad K, Waisbourd M, Katz LJ. Intraocular pressure-independent management of normal tension glaucoma. Surv Ophthalmol 2018; 64:101-110. [PMID: 30300625 DOI: 10.1016/j.survophthal.2018.08.005] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2017] [Revised: 08/15/2018] [Accepted: 08/20/2018] [Indexed: 11/19/2022]
Affiliation(s)
- Jennifer Adeghate
- Wills Eye Hospital, Glaucoma Research Department, Philadelphia, Pennsylvania, USA; Weill Cornell Medical College, Department of Ophthalmology, New York, New York, USA
| | - Kamran Rahmatnejad
- Wills Eye Hospital, Glaucoma Research Department, Philadelphia, Pennsylvania, USA
| | - Michael Waisbourd
- Wills Eye Hospital, Glaucoma Research Department, Philadelphia, Pennsylvania, USA; Thomas Jefferson University, Department of Ophthalmology, Philadelphia, Pennsylvania, USA; Tel-Aviv University Medical Center, Glaucoma Research Center, Tel-Aviv, Israel
| | - L Jay Katz
- Wills Eye Hospital, Glaucoma Research Department, Philadelphia, Pennsylvania, USA; Thomas Jefferson University, Department of Ophthalmology, Philadelphia, Pennsylvania, USA.
| |
Collapse
|
4
|
Spaeth GL. Proper Outcome Measurements regarding Glaucoma: The Inadequacy of using Intraocular Pressure Alone. Eur J Ophthalmol 2018; 6:101-5. [PMID: 8823579 DOI: 10.1177/112067219600600201] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Physicians typically assess glaucoma treatment in terms of the effect on intraocular pressure (IOP). However, it is inappropriate to use IOP as the sole outcome measure for the management of glaucoma for several reasons: a) it is a precursor of disease, but not the disease itself. b) Most often, it is not the only factor responsible for glaucomatous damage. c) It suggests, wrongly, that IOP should be maximally lowered in all glaucoma patients. d) We are beginning to be able to assess more accurately other signs, not just precursors, of glaucomatous damage itself, most importantly, optic disc damage and visual field loss. Even though these signs are far more valuable than IOP in assessing the outcome of treatment, they, too, nevertheless, are ultimately subordinate to the effect of treatment on the patient's quality of life.
Collapse
Affiliation(s)
- G L Spaeth
- Glaucoma Service, Wills Eye Hospital, Philadelphia, PA, USA
| |
Collapse
|
5
|
Turaçli ME, Ozden RG, Gürses MA. The Effect of Betaxolol on Ocular Blood Flow and Visual Fields in Patients with Normotension Glaucoma. Eur J Ophthalmol 2018; 8:62-6. [PMID: 9673472 DOI: 10.1177/112067219800800202] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Purpose This study investigated the effect of ophthalmic betaxolol, a ß, selective adrenoceptor antagonist, on ocular blood flow and visual function in patients with normotension glaucoma (NTG). Methods Thirty-six eyes of eighteen patients with NTG, but otherwise free of systemic disease, were included. Blood fibrinogen, sedimentation rates, Goldmann intraocular pressure, Humphrey automated perimetry, and color Doppler imaging were done at baseline and after one year of twice-daily bilateral topical ocular dosing with 0.5% betaxolol HCl. Results After treatment, the resistivity index of the ophthalmic artery was significantly reduced, and visual fields were significantly improved. The resistivity indexes of the central retinal artery and posterior ciliary artery were also reduced but did not achieve statistical significance. Intraocular pressure was significantly reduced. There was no change in blood fibrinogen and sedimentation rates. Conclusions These findings indicate that long-term treatment with ophthalmic betaxolol improves ocular hemodynamics by lowering the resistivity index of the ophthalmic artery and results in an improvement in the visual fields of patients with NTG. In view of this positive effect on blood flow and visual function, betaxolol is recommended in the management of patients with NTG.
Collapse
Affiliation(s)
- M E Turaçli
- Department of Ophthalmology, University of Ankara, School of Medicine, Turkey
| | | | | |
Collapse
|
6
|
Montanari P, Marangoni P, Oldani A, Ratiglia R, Raiteri M, Berardinelli L. Color Doppler Imaging Study in Patients with Primary Open-Angle Glaucoma Treated with Timolol 0.5% and Carteolol 2%. Eur J Ophthalmol 2018; 11:240-4. [PMID: 11681502 DOI: 10.1177/112067210101100305] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Purpose To evaluate with color Doppler imaging (CDI), in patients with primary open-angle glaucoma (PDAG), the possible influence on ocular hemodynamics of a beta-blocking agent with intrinsic sympathomimetic acitivity (carteolol 2%) compared to a beta-blocker agent without this activity. Methods A study was carried out on 20 patients, with bilateral POaG, intraocular pressure (IOP) ≤ 20 mmHg, all treated twice a day with timolol maleate 0.5% ophthalmic solution. The visual field was evaluated (Octopus 2000 perimeter, G1 program) examining the mean sensitivity (MS) and the mean defect (MD). CDI was carried out to evaluate the resistance index of the internal carotid artery (ICA), the ophthalmic artery (OA), the central retinal artery (CRA), and the short posterior ciliary arteries (SPCA). After these examinations, the therapy was changed to carteolol 2% twice a day. After six months of treatment the examinations were repeated. The data were analysed statistically using Student's t test. Results The mean intraocular pressure during treatment with timolol 0.5% was 16.7 ± 1.67 mmHg and 16.33 ± 1.72 mmHg after treatment with carteolol 2%, the difference not being significant (p=0.494). After six months of treatment with carteolol 2% the MS increased significantly from 22.4 ± 2.5 dB to 24.1 ± 1.8 dB (p=0.018), and the mean defect (MD) fell from 5.3 ± 0.8 dB to 4.7 ± 0.6 dB (p=0.011). There was no significant difference in the resistance index of the CA, the OA and the CRA with the two treatments, whereas the resistance index of the SPCA dropped significantly, from 0.80 ± 0.05 to 0.77 ± 0.02 (p = 0.017). Conclusions CDI did not show significant differences in the resistance indexes of the internal CA, the OA, and the CRA after treatment with carteolol 2% but the resistance index of the SPCA was significantly reduced. Carteolol 2% induced significant changes in the perimetric indexes examined, with an increase in MS and a decrease in MD. These findings suggest that the intrinsic sympathomimetic activity of carteolol may reduce peripheral vascular resistance of the SCA, thus improving perfusion of the optic nerve head, with a protective effect on visual function.
Collapse
Affiliation(s)
- P Montanari
- Eye Clinic of the University of Milano, Italy.
| | | | | | | | | | | |
Collapse
|
7
|
Erkin EF, Tarhan S, Kayikçioğlu OR, Deveci H, Güler C, Göktan C. Effects of Betaxolol and Latanoprost on Ocular Blood flow and Visual Fields in Patients with Primary Open-Angle Glaucoma. Eur J Ophthalmol 2018; 14:211-9. [PMID: 15206646 DOI: 10.1177/112067210401400305] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Purpose To evaluate the effects of betaxolol and latanoprost on ocular blood flow and visual fields in patients with primary open-angle glaucoma (POAG) by means of an obseiver-masked, prospective clinical study. METHODS Thirty-two patients with newly diagnosed POAG were included in the study. The patients were randomized into two groups. The first group was treated with betaxolol 0.50% twice daily and the second group with latanoprost 0.005% once daily. Baseline and post-treatment examinations on the first and third months of treatment included intraocular pressure (IOP) measurement, automated visual field testing, and ocular blood flow assessment. For evaluation of visual fields, mean defect and pattern standard deviation indices were used. Ocular blood flow was assessed by means of color Doppler imaging of the central retinal artery (CRA) and the temporal short posterior ciliary artery (PCA). For each vessel, peak systolic (PSV) and end-diastolic (EDV) blood flow velocities were measured and resistivity index (RI) calculated. Results After exclusion of one noncompliant patient, the study was completed with 31 eyes of 31 patients. Both drugs significantly reduced IOP (p<0.05). The mean IOP lowering effect of latanoprost was significantly higher than that of betaxolol (p=0.03). Visual field indices exhibited no significant changes in either group (p>0.05). There were no significant changes in PSV or EDV measurements of CRA or PCA in either group (p>0.05). RI decreased in both CRA and PCA with both drugs. The mean changes between baseline and 3 month blood flow measurements were not significantly different between betaxolol and latanoprost (p>0.05). CONCLUSIONS Over a treatment period of 3 months, both betaxolol and latanoprost tended to improve ocular blood flow without one of them being superior to the other. The results suggest that the direct (non IOP-dependent) influence on ocular circulation is better for betaxolol than for latanoprost. In addition, neither drug caused significant generalized improvements in visual fields during this period.
Collapse
Affiliation(s)
- E F Erkin
- Department of Ophthalmology, Celal Bayar University, Manisa, Turkey.
| | | | | | | | | | | |
Collapse
|
8
|
Abstract
BACKGROUND Glaucoma is a heterogeneous group of conditions involving progressive damage to the optic nerve, deterioration of retinal ganglion cells, and ultimately visual field loss. It is a leading cause of blindness worldwide. Open angle glaucoma (OAG), the most common form of glaucoma, is a chronic condition that may or may not present with increased intraocular pressure (IOP). Neuroprotection for glaucoma refers to any intervention intended to prevent optic nerve damage or cell death. OBJECTIVES The objective of this review was to systematically examine the evidence regarding the effectiveness of neuroprotective agents for slowing the progression of OAG in adults compared with no neuroprotective agent, placebo, or other glaucoma treatment. SEARCH METHODS We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register) (2016, Issue 7), Ovid MEDLINE, Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE Daily (January 1946 to August 2016), Embase (January 1980 to August 2016), Latin American and Caribbean Literature on Health Sciences (LILACS) (January 1982 to August 2016), the ISRCTN registry (www.isrctn.com/editAdvancedSearch), ClinicalTrials.gov (www.clinicaltrials.gov), and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 16 August 2016. SELECTION CRITERIA We included randomised controlled trials (RCTs) in which topical or oral treatments were used for neuroprotection in adults with OAG. Minimum follow-up time was four years. DATA COLLECTION AND ANALYSIS Two review authors independently reviewed titles and abstracts from the literature searches. We obtained full-text copies of potentially relevant studies and re-evaluated for inclusion. Two review authors independently extracted data related to study characteristics, risk of bias, and outcomes. We identified one trial for this review, thus we performed no meta-analysis. Two studies comparing memantine to placebo are currently awaiting classification until study investigators provide additional study details. We documented reasons for excluding studies from the review. MAIN RESULTS We included one multicenter RCT of adults with low-pressure glaucoma (Low-pressure Glaucoma Treatment Study, LoGTS) conducted in the USA. The primary outcome was progression of visual field loss after four years of treatment with either brimonidine or timolol. Of the 190 adults enrolled in the study, the investigators excluded 12 (6.3%) after randomization; 77 participants (40.5%) did not complete four years of follow-up. The rate of attrition was unbalanced between groups with more participants dropping out of the brimonidine group (55%) than the timolol group (29%).Of those remaining in the study at four years, participants assigned to brimonidine showed less progression of visual field loss than participants assigned to timolol (risk ratio (RR) 0.35, 95% confidence interval (CI) 0.14 to 0.86; 101 participants). Because of high risk of attrition bias and potential selective outcome reporting, we graded the certainty of evidence for this outcome as very low. At the four-year follow-up, the mean IOP was similar in both groups among those for whom data were available (mean difference 0.20 mmHg, 95% CI -0.73 to 1.13; 91 participants; very low-certainty evidence). The study authors did not report analyzable data for visual acuity or any data related to vertical cup-disc ratio, quality of life, or economic outcomes. The most frequent adverse event was ocular allergy to the study drug, which affected more participants in the brimonidine group than the timolol group (RR 5.32, 95% CI 1.64 to 17.26; 178 participants; very low-certainty evidence). AUTHORS' CONCLUSIONS Although the only trial we included in this review found less visual field loss in the brimonidine-treated group, the evidence was of such low certainty that we can draw no conclusions from this finding. Further clinical research is needed to determine whether neuroprotective agents may be beneficial for individuals with OAG. Such research should focus on outcomes important to patients, such as preservation of vision, and how these outcomes relate to cell death and optic nerve damage. As OAG is a chronic, progressive disease with variability in symptoms, RCTs designed to measure the effectiveness of neuroprotective agents require a long-term follow-up of five years or longer to detect clinically meaningful effects.
Collapse
Affiliation(s)
- Dayse F Sena
- Massachusetts Eye and Ear Infirmary243 Charles St, Connecting Building 703BostonMassachusettsUSA02114
| | - Kristina Lindsley
- Johns Hopkins Bloomberg School of Public HealthDepartment of Epidemiology615 North Wolfe Street, Mail Room E6132BaltimoreMarylandUSA21205
| | | |
Collapse
|
9
|
Abstract
BACKGROUND Glaucoma is a heterogeneous group of conditions involving progressive damage to the optic nerve, deterioration of retinal ganglion cells and ultimately visual field loss. It is a leading cause of blindness worldwide. Open angle glaucoma (OAG), the commonest form of glaucoma, is a chronic condition that may or may not present with increased intraocular pressure (IOP). Neuroprotection for glaucoma refers to any intervention intended to prevent optic nerve damage or cell death. OBJECTIVES The objective of this review was to systematically examine the evidence regarding the effectiveness of neuroprotective agents for slowing the progression of OAG in adults. SEARCH METHODS We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2012, Issue 9), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE, (January 1950 to October 2012), EMBASE (January 1980 to October 2012), Latin American and Caribbean Literature on Health Sciences (LILACS) (January 1982 to October 2012), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. The electronic databases were last searched on 16 October 2012. SELECTION CRITERIA We included randomized controlled trials (RCTs) in which topical or oral treatments were used for neuroprotection in adults with OAG. Minimum follow up time was four years. DATA COLLECTION AND ANALYSIS Two review authors independently reviewed titles and abstracts from the literature searches. Full-text copies of potentially relevant studies were obtained and re-evaluated for inclusion. Two review authors independently extracted data related study characteristics, risk of bias, and outcome data. One trial was identified for this review, thus we performed no meta-analysis. Two studies comparing memantine to placebo are currently awaiting classification until additional study details are provided. We documented reasons for excluding studies from the review. MAIN RESULTS We included one multi-center RCT of adults with low-pressure glaucoma (Low-pressure Glaucoma Treatment Study, LoGTS) conducted in the USA. The primary outcome was visual field progression after four years of treatment with either brimonidine or timolol. Of the 190 adults enrolled in the study, 12 (6.3%) were excluded after randomization and 77 (40.5%) did not complete four years of follow up. The rate of attrition was unbalanced between groups with more participants dropping out of the brimonidine group (55%) than the timolol group (29%). Of those remaining in the study at four years, participants assigned to brimonidine showed less visual field progression than participants assigned to timolol (5/45 participants in the brimonidine group compared with 18/56 participants in the timolol group). Since no information was available for the 12 participants excluded from the study, or the 77 participants who dropped out of the study, we cannot draw any conclusions from these results as the participants for whom data are missing may or may not have progressed. The mean IOP was similar in both groups at the four-year follow up among those for whom data were available: 14.2 mmHg (standard deviation (SD) = 1.9) among the 43 participants in the brimonidine group and 14.0 mmHg (SD = 2.6) among the 48 participants in the timolol group. Among the participants who developed progressive visual field loss, IOP reduction of 20% or greater was not significantly different between groups: 4/9 participants in the brimonidine group and 12/31 participants in the timolol group. The study authors did not report data for visual acuity or vertical cup-disc ratio. The most frequent adverse event was ocular allergy to study drug, which occurred more frequently in the brimonidine group (20/99 participants) than the timolol group (3/79 participants). AUTHORS' CONCLUSIONS Although neuroprotective agents are intended to act as pharmacological antagonists to prevent cell death, this trial did not provide evidence that they are effective in preventing retinal ganglion cell death, and thus preserving vision in people with OAG. Further clinical research is needed to determine whether neuroprotective agents may be beneficial for individuals with OAG. Such research should focus outcomes important to patients, such as preservation of vision, and how these outcomes relate to cell death and optic nerve damage. Since OAG is a chronic, progressive disease with variability in symptoms, RCTs designed to measure the effectiveness of neuroprotective agents would require long-term follow up (more than four years) in order to detect clinically meaningful effects.
Collapse
Affiliation(s)
- Dayse F Sena
- Massachusetts Eye and Ear Infirmary, Boston,Massachusetts,
| | | |
Collapse
|
10
|
Mayama C, Araie M. Effects of antiglaucoma drugs on blood flow of optic nerve heads and related structures. Jpn J Ophthalmol 2013; 57:133-49. [PMID: 23321913 DOI: 10.1007/s10384-012-0220-x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2012] [Accepted: 10/01/2012] [Indexed: 11/28/2022]
Abstract
An association between glaucoma development or progression and compromised ocular blood flow has been postulated as a result of population-based studies and prospective cohort studies. Blood flow in the optic nerve head (ONH) is of primary importance in the pathogenesis of glaucoma. The potential to modify the blood flow in the ONH and its related structures has been reported in various agents, including topical antiglaucoma drugs and systemic drugs such as calcium channel antagonists, which are reviewed in this manuscript. Clinical implications of the improvement in ocular blood flow on the treatment of glaucomatous optic neuropathy require further investigation.
Collapse
Affiliation(s)
- Chihiro Mayama
- Department of Ophthalmology, The University of Tokyo School of Medicine, Tokyo, Japan
| | | |
Collapse
|
11
|
Yamazaki Y, Hayamizu F. Effect of trabeculectomy on retrobulbar circulation and visual field progression in patients with primary open-angle glaucoma. Clin Ophthalmol 2012; 6:1539-45. [PMID: 23055676 PMCID: PMC3460708 DOI: 10.2147/opth.s36331] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
Abstract
Background The purpose of this study was to investigate the relationship between retrobulbar circulation and visual field change in eyes with primary open-angle glaucoma following unilateral trabeculectomy. Methods Twenty-one patients with primary open-angle glaucoma were prospectively enrolled. Retrobulbar circulation was evaluated using color Doppler imaging. The peak systolic velocity, end-diastolic velocity, and resistive index were evaluated in the central retinal artery, temporal site of the short posterior ciliary artery (t-SPCA), and nasal site of the short posterior ciliary artery (n-SPCA). Visual field examinations were performed using a Humphrey visual field analyzer before surgery and trimonthly for 12 months postoperatively. Results In the operative eyes, the end-diastolic velocity was significantly increased in the central retinal artery (P = 0.005, analysis of variance), t-SPCA (P = 0.005), and n-SPCA (P = 0.027). The resistive index was significantly decreased in the central retinal artery (P = 0.003), t-SPCA (P = 0.000), and n-SPCA (P = 0.010) postoperatively compared with preoperatively. The nonoperative contralateral eyes did not show a significant change in end-diastolic velocity or resistive index for either the SPCA or central retinal artery. The mean deviation slope in the operative eyes (−0.26 ± 0.64 dB/year) was significantly slower than that in the nonoperative eyes (−0.65 ± 0.70 dB/year; P = 0.047, Mann-Whitney U test). Conclusion These results suggest that trabeculectomy improves the retrobulbar circulation and prevents the progression of visual field changes in patients with primary open-angle glaucoma.
Collapse
Affiliation(s)
- Yoshio Yamazaki
- Department of Ophthalmology, Division of Visual Science, Nihon University School of Medicine, Tokyo, Japan
| | | |
Collapse
|
12
|
Januleviciene I, Siaudvytyte L, Diliene V, Barsauskaite R, Paulaviciute-Baikstiene D, Siesky B, Harris A. Comparison of intraocular pressure, blood pressure, ocular perfusion pressure and blood flow fluctuations during dorzolamide versus timolol add-on therapy in prostaglandin analogue treated glaucoma subjects. Pharmaceuticals (Basel) 2012; 5:325-38. [PMID: 24281382 PMCID: PMC3763637 DOI: 10.3390/ph5030325] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2011] [Revised: 03/07/2012] [Accepted: 03/19/2012] [Indexed: 11/18/2022] Open
Abstract
Objective: To compare the effects of dorzolamide and timolol add-on therapy in open-angle glaucoma (OAG) patients previously treated with prostaglandin analogue (Pg), by evaluating fluctuations in the intraocular (IOP), blood (BP), ocular perfusion pressures (OPP) and retrobulbar blood flow (RBF) parameters. Methods: 35 OAG patients (35 eyes), 31 women (88.6%) age 63.3 (8.9) years were evaluated in a 3 month randomized, cross-over, single-masked study. During the experiments BP, heart rate, IOP and OPP were assessed 4 times per day (8–12–16–20 h). RBF was measured twice per day (8–20 h) using Color Doppler imaging in the ophthalmic (OA), central retinal (CRA), nasal (nSPCA) and temporal (tSPCA) posterior ciliary arteries. In each vessel, peak systolic velocity (PSV) and end-diastolic velocity (EDV) were assessed and vascular resistance (RI) calculated. Results: Both add-on therapies lowered IOP in a statistically significant manner from 15.7 ± 2.4 mmHg at latanoprost baseline to 14.9 ± 2.2 mmHg using dorzolamide (p < 0.001) and 14.2 ± 1.9 mmHg using timolol (p < 0.001). The IOP lowering effect was statistically significant at 20 h, favoring timolol as compared to dorzolamide (1.4 ± 2.4 vs. 0.2 ± 2.1 mmHg), (p < 0.05). Dorzolamide add-on therapy showed smaller IOP (2.0 ± 1.4), SPP (13.3 ± 7.9), systolic BP (13.5 ± 8.7) and diastolic BP (8.4 ± 5.4) fluctuations as compared to both latanoprost baseline or timolol add-on therapies. Higher difference between morning and evening BP was correlated to decreased evening CRA EDV in the timolol group (c = −0.41; p = 0.01). With increased MAP in the morning or evening hours, we found increased evening OA RI in timolol add-on group (c = 0.400, p = 0.02; c = 0.513, p = 0.002 accordingly). Higher MAP fluctuations were related to impaired RBF parameters during evening hours-decreased CRA EDV (c = −0.408; p = 0.01), increased CRA RI (c = 0.576; p < 0.001) and tSPCA RI (c = 0.356; p = 0.04) in the dorzolamide group and increased nSPCA RI (c = 0.351; p = 0.04) in the timolol add-on group. OPP fluctuations correlated with increased nSPCA RI (c = 0.453; p = 0.006) in the timolol group. OPP fluctuations were not related to IOP fluctuations in both add-on therapies (p < 0.05). Conclusions: Both dorzolamide and timolol add-on therapies lowered IOP in a statistically significant fashion dorzolamide add-on therapy showed lower fluctuations in IOP, SPP and BP. Higher variability of daytime OPP led to impaired RBF parameters in the evening.
Collapse
Affiliation(s)
- Ingrida Januleviciene
- Department of Ophthalmology, Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Eye Clinic of Kaunas University of Medicine, Eiveniu Str. 2, Kaunas 50009, Lithuania
- Authors to whom correspondence should be addressed; (I.J.); (A.H.); Tel.: +370-3732-6760 (I.J.); Tel.:+1-317-278-0177 (A.H.); Fax: +1-317-278-1007 (A.H.)
| | - Lina Siaudvytyte
- Department of Ophthalmology, Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Eye Clinic of Kaunas University of Medicine, Eiveniu Str. 2, Kaunas 50009, Lithuania
| | - Vaida Diliene
- Department of Ophthalmology, Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Eye Clinic of Kaunas University of Medicine, Eiveniu Str. 2, Kaunas 50009, Lithuania
| | - Ruta Barsauskaite
- Department of Ophthalmology, Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Eye Clinic of Kaunas University of Medicine, Eiveniu Str. 2, Kaunas 50009, Lithuania
| | - Daiva Paulaviciute-Baikstiene
- Department of Ophthalmology, Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Eye Clinic of Kaunas University of Medicine, Eiveniu Str. 2, Kaunas 50009, Lithuania
| | - Brent Siesky
- Glaucoma Research and Diagnostic Center, Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | - Alon Harris
- Glaucoma Research and Diagnostic Center, Indiana University School of Medicine, Indianapolis, IN 46202, USA
- Authors to whom correspondence should be addressed; (I.J.); (A.H.); Tel.: +370-3732-6760 (I.J.); Tel.:+1-317-278-0177 (A.H.); Fax: +1-317-278-1007 (A.H.)
| |
Collapse
|
13
|
Puerto-Hernández B, Rebolleda G, García-Pérez JL, Muñoz-Negrete FJ, González-Gordaliza C. [Effect on ocular blood flow of Combigan® versus placebo in patients with ocular hypertension]. ARCHIVOS DE LA SOCIEDAD ESPANOLA DE OFTALMOLOGIA 2011; 86:42-46. [PMID: 21440829 DOI: 10.1016/j.oftal.2010.07.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/30/2009] [Accepted: 06/18/2010] [Indexed: 05/30/2023]
Abstract
PURPOSE This study was undertaken to compare the ocular haemodynamic effects of Combigan(®) versus placebo in patients with ocular hypertension (OHT). METHODS Thirty patients with OHT were included in a controlled, randomised, double blind study in two parallel groups; 15 were randomised to receive Combigan(®) and 15 to receive placebo for a period of 3 months. At baseline and at 3 months retrobulbar blood flowmeasurements of the ophthalmic artery (OA) and central retinal artery (CRA) were taken using colour Doppler imaging(CDI) ultrasound, concurrently with intraocular pressure (IOP). RESULTS Combigan(®) significantly reduced IOP after 3 months of treatment (P = 0.001), whereas placebo showed no significant change in IOP. The baseline haemodynamic parameters were similar between treatment and placebo groups. Patients treated with Combigan® showed a statistically significant decrease in CRA resistive index (P = 0.007). CONCLUSIONS Patients treated for 3 months with Combigan(®) showed a significant decrease of CRA resistive index that could be explained by the decrease in IOP.
Collapse
Affiliation(s)
- B Puerto-Hernández
- Servicio de Oftalmología, Unidad de Glaucoma, IRYCIS, Hospital Ramón y Cajal, Madrid, España.
| | | | | | | | | |
Collapse
|
14
|
|
15
|
Moss AM, Harris A, Siesky B, Rusia D, Williamson KM, Shoshani Y. Update and critical appraisal of combined timolol and carbonic anhydrase inhibitors and the effect on ocular blood flow in glaucoma patients. Clin Ophthalmol 2010; 4:233-41. [PMID: 20463789 PMCID: PMC2861928 DOI: 10.2147/opth.s6372] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Topical hypotensive therapy with both timolol and carbonic anhydrase inhibitors has been shown to be efficacious at reducing intraocular pressure. Many prospective studies have also suggested that carbonic anhydrase inhibitors augment ocular blood flow and vascular regulation independent of their hypotensive effects. Although consistent in their findings, these studies must be cautiously interpreted due to the limitations of study design and specific blood flow imaging modalities. The purpose of this review is to appraise and critically evaluate the current body of literature investigating the effects of combined treatment with topical carbonic anhydrase inhibitors and timolol in patients with glaucoma with respect to ocular blood flow, visual function, and optic nerve head structure.
Collapse
Affiliation(s)
- Adam M Moss
- Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana, USA
| | | | | | | | | | | |
Collapse
|
16
|
Sycha T, Vass C, Findl O, Bauer P, Groke I, Schmetterer L, Eichler H. WITHDRAWN: Interventions for normal tension glaucoma. Cochrane Database Syst Rev 2010; 2010:CD002222. [PMID: 20166063 PMCID: PMC10734265 DOI: 10.1002/14651858.cd002222.pub2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND Normal tension glaucoma is a clinical condition in which the optic nerve is pathologically excavated and the visual field is disturbed. Nevertheless it has been assumed that intraocular pressure plays a role in the progression of visual field defects in this disease, but other, mainly vascular factors, have been discussed as well. OBJECTIVES The objective of this review is to assess the effects of medical and surgical treatments for normal tension glaucoma. SEARCH STRATEGY Trials were identified from the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Group trials register), MEDLINE, EMBASE and BIOSIS Previews. Bibliographies of identified trials were searched to find additional trials. In addition, investigators and pharmaceutical companies were contacted. Date of last search: January 2001. SELECTION CRITERIA This review includes randomised controlled trials in which medical or surgical interventions were compared to no treatment, placebo or other treatment in people with normal tension glaucoma. DATA COLLECTION AND ANALYSIS Data were extracted by two reviewers and results were compared for differences. Discrepancies were resolved by discussion. The heterogeneity of interventions, follow-up periods and outcomes did not allow for statistical combinations of the study results. MAIN RESULTS According to the selection criteria on visual field loss, eight studies were included in this review. Only three studies focussed on patient relevant outcomes. In one trial a beneficial effect of lowering intraocular pressure was found, but only if data were corrected for cataract development. In two small studies a beneficial effect on visual field loss of brovincamine, a calcium antagonist was reported. AUTHORS' CONCLUSIONS In one study the effect of intraocular pressure lowering on visual field outcome was only significant when data were corrected for cataract development. The results for calcium antagonists are promising, but larger trials have to be performed. Studies that focussed on reduction of intraocular pressure or haemodynamic variables are not necessarily relevant for the outcome in people with normal tension glaucoma.
Collapse
Affiliation(s)
- Thomas Sycha
- Medical University of ViennaDepartment of NeurologyWähringer Gürtel 18‐20ViennaAustriaA‐1090
| | - Clemens Vass
- Medical University of ViennaDepartment of OphthalmologyWähringer Gürtel 18‐20ViennaAustriaA‐1090
| | - Oliver Findl
- Hanusch HospitalDepartment of OphthalmologyHeinrich‐Collin‐Strasse 30ViennaAustriaA‐1140
| | - Peter Bauer
- Medical University of ViennaInstitute of Medical StatisticsSpitalgasse23ViennaAustriaA‐1090
| | - Ilse Groke
- Medical University of ViennaZentralbibliothek fur Medizin, IVSWahringer Gurtel 18‐20ViennaAustriaA‐1090
| | - Leopold Schmetterer
- Medical University of ViennaInstitute of Medical Physics, Department of Clinical PharmacologyWähringer Gürtel 18‐20ViennaAustriaA‐1090
| | - Hans‐Georg Eichler
- Medical University of ViennaDepartment of Clinical PharmacologyAllgemeines KrankenhausWähringer Gürtel 18‐20ViennaAustriaA‐1090
| | | |
Collapse
|
17
|
Abstract
BACKGROUND Glaucoma is a heterogeneous group of conditions involving progressive damage to the optic nerve, deterioration of retinal ganglion cells and ultimately visual field loss. It is a leading cause of blindness worldwide. Open angle glaucoma (OAG), the commonest form of glaucoma, is a chronic condition that may or may not present with increased intraocular pressure (IOP). Neuroprotection for glaucoma refers to any intervention intended to prevent optic nerve damage or cell death. The treatment can target extracellular factors such as reducing IOP, or cellular factors derived from the optic nerve itself such as blocking intracellular death signals. OBJECTIVES The objective of this review was to systematically examine the evidence regarding the effectiveness of neuroprotective agents, either topical or oral, for slowing the progression of OAG in adults. SEARCH STRATEGY We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library, Issue 4, 2009), MEDLINE (January 1960 to January 2010), EMBASE (January 1980 to January 2010), Latin American and Caribbean Literature on Health Sciences (LILACS) (January 1982 to January 2010) and ClinicalTrials.gov (http://clinicaltrials.gov). (5 January 2010). There were no language or date restrictions in the search for trials. The electronic databases were last searched on 5 January 2010. SELECTION CRITERIA This review was limited to randomized controlled trials (RCTs) in which topical or oral treatments were used to prevent retinal ganglion cell death. Our population of interest was adults with OAG. As the primary outcome for this review was the proportion of participants who developed any progression of visual field loss at five years post intervention, only trials with at least five years of follow-up were included. DATA COLLECTION AND ANALYSIS Two review authors independently reviewed titles and abstracts from the literature searches. Full text copies of relevant or potentially relevant studies were obtained and re-evaluated for inclusion. There were no trials identified for this review, thus we performed no data extraction or meta-analysis. Two studies comparing memantine to placebo are currently awaiting classification until additional study details are provided. Reasons for excluding studies from the review were documented. MAIN RESULTS In accordance with the selection criteria for inclusion, we identified no studies relevant for this review. The results of short-term trials and other studies are discussed in this review. AUTHORS' CONCLUSIONS Although neuroprotective agents are intended to act as pharmacological antagonists to prevent cell death, the evidence that they are effective in preventing retinal ganglion cell death, and thus preserving vision in patients with OAG, has not been demonstrated. Long-term RCTs are needed to determine whether or not neuroprotective agents may be beneficial for individuals with OAG.
Collapse
Affiliation(s)
- Dayse F Sena
- Massachusetts Eye and Ear Infirmary, Massachusetts, Boston, USA
| | | | - Kristina Lindsley
- Center for Clinical Trials, Johns Hopkins University Bloomberg School of Public Health, Maryland, Baltimore, USA
| |
Collapse
|
18
|
Beckers HJM, Schouten JS, Webers CAB. Role of fixed-combination brinzolamide 1%/timolol 0.5% in the treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension. Clin Ophthalmol 2009; 3:593-9. [PMID: 19898664 PMCID: PMC2773281 DOI: 10.2147/opth.s4853] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2009] [Indexed: 11/23/2022] Open
Abstract
Brinzolamide 1%/timolol 0.5% is a new fixed-combination for the treatment of open-angle glaucoma or ocular hypertension. Brinzolamide/timolol has a favorable safety profile, with an incidence of ocular burning and stinging <5%. Published data show that brinzolamide 1%/timolol 0.5% and dorzolamide 2%/timolol 0.5% have similar efficacies for lowering intraocular pressure (IOP). There is some evidence that brinzolamide/timolol may be more comfortable. Although patients receiving brinzolamide/timolol may experience more blurred vision on instillation, some data show a preference for brinzolamide/timolol over dorzolamide/timolol. Although available data to assess the role of brinzolamide/timolol in daily clinical practice are still limited, these first results suggest the agent to be a reasonable alternative for patients who do not reach target IOP with monotherapy.
Collapse
|
19
|
Ishii K, Fukaya Y, Araie M, Tomita G. Topical administration of iganidipine, a new water-soluble ca2+antagonist, increases ipsilateral optic nerve head circulation in rabbits and cynomolgus monkeys. Curr Eye Res 2009; 29:67-73. [PMID: 15370369 DOI: 10.1080/02713680490513236] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
PURPOSE To evaluate the effects of topically administered iganidipine hydrochloride, a novel water-soluble Ca2+- channel blocker, on optic nerve head (ONH) circulation in Dutch rabbits and cynomolgus monkeys. METHODS ONH tissue blood velocity (NBONH) was determined using the laser speckle method. In rabbits, NBONH was measured for 90 minutes before and after a single iganidipine administration, or before and after twice-daily ad- ministrations for 21 days (0.03%). In monkeys, NBONH was measured before and after twice-daily administrations of iganidipine for 7 days (0.03 or 0.1%). RESULTS Iganidipine (0.03% solution) significantly increased NBONH by 8 to 10% in treated eyes after a single administration (p < 0.05) or by 18 to 35% after 7-, 14-, or 21-day twice-daily administration in rabbits (p < 0.05). In monkeys, 0.03% and 0.1% iganidipine significantly increased NBONH in treated eyes by 20 and 41% after 7-day (p < 0.05) twice-daily administration, respectively. CONCLUSION Topical iganidipine significantly increased ONH blood velocity in treated eyes.
Collapse
Affiliation(s)
- Kiyoshi Ishii
- Eye Clinic, Saitama red Cross Hospital, 8-3-33 Kamiochiai, Chuo-ku, Saitama-si, Saitama 338-0001, Japan.
| | | | | | | |
Collapse
|
20
|
Meta-analysis of medical intervention for normal tension glaucoma. Ophthalmology 2009; 116:1243-9. [PMID: 19450880 DOI: 10.1016/j.ophtha.2009.01.036] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2008] [Revised: 01/14/2009] [Accepted: 01/23/2009] [Indexed: 11/20/2022] Open
Abstract
OBJECTIVE To evaluate the intraocular pressure (IOP) reduction achieved by the most frequently prescribed antiglaucoma drugs in patients with normal tension glaucoma (NTG). DESIGN Systematic review and meta-analysis. PARTICIPANTS Fifteen randomized clinical trials reported 25 arms for peak IOP reduction, 16 arms for trough IOP reduction, and 13 arms for diurnal curve IOP reduction. METHODS Pertinent publications were identified through systematic searches of PubMed, EMBASE, and the Cochrane Controlled Trials Register. The patients had to be diagnosed as having NTG. Methodological quality was assessed by the Delphi list on a scale from 0 to 18. The pooled 1-month IOP-lowering effects were calculated using the 2-step DerSimonian and Laird estimate method of the random effects model. MAIN OUTCOME MEASURES Absolute and relative reductions in IOP from baseline for peak and trough moments. RESULTS Quality scores of included studies were generally high, with a mean quality score of 12.7 (range, 9-16). Relative IOP reductions were peak, 15% (12%-18%), and trough, 18% (8%-27%) for timolol; peak, 14% (8%-19%), and trough, 12% (-7% to 31%) for dorzolamide; peak, 24% (17%-31%), and trough, 11% (7%-14%) for brimonidine; peak, 20% (17%-24%), and trough, 20% (18%-23%) for latanoprost; peak, 21% (16%-25%), and trough, 18% (14%-22%) for bimatoprost. The differences in absolute IOP reductions between prostaglandin analogues and timolol varied from 0.9 to 1.0 mmHg at peak and -0.1 to 0.2 mmHg at trough. CONCLUSIONS Latanoprost, bimatoprost, and timolol are the most effective IOP-lowering agents in patients with NTG.
Collapse
|
21
|
|
22
|
Evans DW, Bartlett JD, Houde B, Than TP, Shaikh A. Latanoprost-Induced Stabilization of Central Visual Function in Patients with Primary Open-Angle Glaucoma. J Ocul Pharmacol Ther 2008; 24:224-9. [DOI: 10.1089/jop.2007.0106] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- David W. Evans
- Department of Optometry, School of Optometry, University of Alabama at Birmingham, Birmingham, AL
| | - Jimmy D. Bartlett
- Department of Optometry, School of Optometry, University of Alabama at Birmingham, Birmingham, AL
- Department of Pharmacology and Toxicology, School of Medicine, University of Alabama, Birmingham, AL
| | | | | | | |
Collapse
|
23
|
Rolle T, Tofani F, Brogliatti B, Grignolo FM. The effects of dorzolamide 2% and dorzolamide/timolol fixed combination on retinal and optic nerve head blood flow in primary open-angle glaucoma patients. Eye (Lond) 2008; 22:1172-9. [DOI: 10.1038/sj.eye.6703071] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
24
|
Riva CE, Schmetterer L. Microcirculation of the Ocular Fundus. Microcirculation 2008. [DOI: 10.1016/b978-0-12-374530-9.00018-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
|
25
|
Martinez A, Sanchez M. Retrobulbar haemodynamic effects of the latanoprost/timolol and the dorzolamide/timolol fixed combinations in newly diagnosed glaucoma patients. Int J Clin Pract 2007; 61:815-25. [PMID: 17343668 DOI: 10.1111/j.1742-1241.2006.01126.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
The objective of this study was to compare the effect of the latanoprost/timolol fixed combination (LTFC) and the dorzolamide/timolol fixed combination (DTFC) on the retrobulbar haemodynamic and intraocular pressure (IOP) in patents with open-angle glaucoma (OAG). This was a prospective, examiner masked, randomised and crossover study. Participants were 32 consecutive subjects, who met the inclusion/exclusion criteria, with newly diagnosed OAG. Patients were randomised to either LTFC or DTFC for the first 1-month treatment phase after a 1-month washout period, without medical treatment, patients began with the opposite treatment for the second 1-month treatment period. Colour Doppler parameters in ophthalmic artery (OA) and posterior ciliary arteries (PCA), ocular perfusion pressure, IOP and systemic haemodynamics were assessed at each baseline and at the end of each treatment period. The main outcomes include peak systolic velocity (PSV), end-diastolic velocity (EDV) and resistance index (RI) in OA and PCA. DTFC significantly increased EDV in OA from 7.55 (1.16) to 9.32 (1.22), p<0.0001, and in the PCA from 4.41 (0.70) to 5.36 (0.60), p<0.0001, and significantly decreased RI in OA from 0.775 (0.036) to 0.725 (0.032), p<0.0001, and in the PCA from 0.694 (0.045) to 0.634 (0.034). LTFC significantly decreased the EDV and significantly increased RI in PCA, p=0.0076 and p=0.0009, respectively. There were no statistical significant differences in the IOP lowering effect between both treatments. DTFC seems to have a beneficial vascular effect on retrobulbar vessels in OAG patients.
Collapse
Affiliation(s)
- A Martinez
- Instituto Gallego de Oftalmología, C/ Ramón Baltar sn, Santiago de Compostela, La Coruña, Spain.
| | | |
Collapse
|
26
|
Liu JHK, Li R, Nelson TR, Weinreb RN. Resistance to Blood Flow in the Rabbit Ophthalmic Artery After Topical Treatment with Timolol. J Ocul Pharmacol Ther 2007; 23:103-9. [PMID: 17444797 DOI: 10.1089/jop.2006.0098] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
PURPOSE The aim of this study was to investigate the resistance to blood flow in the ophthalmic artery of rabbits receiving topical treatment with timolol. METHODS Eight (8) New Zealand albino rabbits received 20 mul of timolol treatment (vehicle, 0.1%, 0.33%, 1%, and 3.3%) on the right eye. Blood-flow velocity in the ophthalmic artery was determined in the treated eye using color Doppler imaging (CDI) with a 12-MHz linear ultrasound transducer prior to the treatment and at 0.5, 1, 1.5, 2, and 3 h after the treatment. Intraocular pressure (IOP) was measured in both eyes, using a pneumatonometer at the same time points. Pourcelot's resistive index of blood flow was calculated, using the peak systolic velocity and the end diastolic velocity. A control experiment was performed with CDI obtained from the right eye when the left eye was treated with 1% timolol. RESULTS In the eye treated with 1% and 3.3% timolol, a dose-dependent increase in the resistive index of blood flow occurred in the ophthalmic artery. No change in the resistive index occurred when the contralateral eye was treated with 1% timolol. Changes of IOP were not different between the two eyes under all the experimental conditions. Timolol, at all concentrations, caused a significant reduction of heart rate. A similar reduction of heart rate occurred when either eye was treated with 1% timolol. CONCLUSIONS Topical treatment with timolol in rabbits can increase the resistance to blood flow in the ophthalmic artery. This effect is caused by a mechanism local to the eye and is not dependent on an IOP change.
Collapse
Affiliation(s)
- John H K Liu
- Hamilton Glaucoma Center and Department of Ophthalmology, University of California-San Diego, La Jolla, CA 92039-0946, USA.
| | | | | | | |
Collapse
|
27
|
Detorakis ET, Achtaropoulos AK, Drakonaki EE, Kozobolis VP. Hemodynamic evaluation of the posterior ciliary circulation in exfoliation syndrome and exfoliation glaucoma. Graefes Arch Clin Exp Ophthalmol 2006; 245:516-21. [PMID: 17111150 DOI: 10.1007/s00417-006-0439-7] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2005] [Revised: 05/24/2006] [Accepted: 08/07/2006] [Indexed: 11/26/2022] Open
Abstract
BACKGROUND Previous studies have reported impaired blood flow in the ophthalmic artery (OA) and central retinal artery (CRA) in exfoliation syndrome and exfoliation glaucoma. This study evaluates blood flow at the long and short posterior ciliary arteries (LPCA and SPCA, respectively) in these conditions. METHODS Consecutively examined candidates for cataract surgery were included. Only one eye (OD) was included in the analyses for consistency. Patients were classified into non-glaucoma and non-exfoliation (controls), primary open angle glaucoma (POAG), exfoliation syndrome and exfoliation glaucoma groups, based on the findings of the OD. Sixty-eight patients (41 males, 60.3%) were included. Color Doppler imaging (CDI) of the nasal and temporal branches of LPCA and SPCA was performed using a 7.5 Mhz probe. The peak systolic velocity (PSV), end diastolic velocity (EDV) and resistivity index (RI) were recorded for the examined vessels. RESULTS EDV at the LPCA was significantly lower in exfoliation syndrome and glaucoma, compared with controls and POAG respectively. EDV was significantly lower and RI was significantly higher at the SPCA in exfoliation glaucoma, compared with exfoliation, whereas respective differences were statistically not significant between controls and POAG. CONCLUSIONS The hemodynamic impairment at the LPCA in exfoliation syndrome and glaucoma supports an association between exfoliation and ischemic stress at the anterior ocular segment.
Collapse
|
28
|
Gherghel D, Hosking SL, Cunliffe IA, Armstrong RA. First-line therapy with latanoprost 0.005% results in improved ocular circulation in newly diagnosed primary open-angle glaucoma patients: a prospective, 6-month, open-label study. Eye (Lond) 2006; 22:363-9. [PMID: 17115020 DOI: 10.1038/sj.eye.6702639] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
PURPOSE To evaluate the effect of latanoprost 0.005% on the optic nerve head (ONH) and retinal circulation of newly diagnosed and previously untreated primary open-angle glaucoma (POAG) patients. METHODS Twenty-two newly diagnosed and previously untreated POAG patients (mean age+/-SD: 68.38+/-11.92 years) were included in this longitudinal open-label study. Patients were treated with latanoprost 0.005% once a day. Intraocular pressure (IOP), systemic blood pressure (BP), mean ocular perfusion pressure (MOPP), and ocular perfusion parameters 'volume', 'velocity', and 'flow' measured at the optic nerve head (ONH) and retina by means of Heidelberg Retina Flowmeter system were evaluated during a 6-month follow-up period. RESULTS Treatment with latanoprost 0.005% resulted in a significant decrease in IOP (P<0.0001) and increase in MOPP (P<0.0001). After correcting for changes in MOPP, the blood velocity measured at the ONH level was significantly higher after 6 months of treatment than at baseline (P=0.0310). In addition, blood volume and flow measured at the peripapillary retina level improved after 3 and 6 months of treatment (P=0.0170; P=0.0260, and P=0.0170; P=0.0240 respectively). CONCLUSION Previously untreated POAG patients exhibit reduced IOP, increased MOPP and improved ocular perfusion at the ONH and retina levels when treated with Latanoprost 0.005%. These effects could be beneficial for glaucoma patients suffering from ocular vascular dysregulation.
Collapse
Affiliation(s)
- D Gherghel
- School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham, UK.
| | | | | | | |
Collapse
|
29
|
Miki H, Miki K. The effects on the intraocular pressure and visual field resulting from a switch in the treatment from timolol to betaxolol. J Ocul Pharmacol Ther 2006; 20:509-17. [PMID: 15684810 DOI: 10.1089/jop.2004.20.509] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Patients with primary open-angle glaucoma (POAG) were dosed twice-daily with 0.5% timolol maleate for 2 years, followed by 2 years of twice-daily dosing with 0.5% betaxolol hydrochloride. The changes in intraocular pressure (IOP) and effects on visual field by each treatment were monitored over this 4-year period. Both the timolol and betaxolol treatments controlled IOP. The mean MD (mean deviation in visual field) values at 24 months of the timolol treatment were -6.18 dB (decibels) and -5.32 dB. Mean MD baseline values following 24 months of the timolol treatment produced 2.31 dB and 0.95 dB reductions in sensitivity in the right and left eyes, and the reduction in the right eye was statistically significant (p < 0.01). The mean MD values after 24 months of the betaxolol treatment were -3.82 dB in the right eyes, an increase of 2.36 dB, and -4.05 dB in the left eyes, up by 1.28 dB. The results from this clinical trial demonstrated that betaxolol was superior over timolol in improving mean retinal sensitivity.
Collapse
Affiliation(s)
- Hirohiko Miki
- Department of Ophthalmology, Kansai Medical University, Moriguchi, Osaka, Japan
| | | |
Collapse
|
30
|
Harris A, Bingaman D, Ciulla TA, Martin B. Retinal and Choroidal Blood Flow in Health and Disease. Retina 2006. [DOI: 10.1016/b978-0-323-02598-0.50011-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
|
31
|
Orgul S, Zawinka C, Gugleta K, Flammer J. Therapeutic Strategies for Normal-Tension Glaucoma. Ophthalmologica 2005; 219:317-23. [PMID: 16286789 DOI: 10.1159/000088372] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2004] [Accepted: 04/28/2004] [Indexed: 11/19/2022]
Abstract
Treatment of normal-tension glaucoma has been a subject of debate for several years. Glaucomatous damage cannot be influenced directly, and current treatment modalities in normal-tension glaucoma are aimed at the control of risk factors. Intraocular pressure is a widely accepted risk factor and its reduction can improve the prognosis in normal-tension glaucoma patients. The repeated demonstration of the importance of hemodynamic factors in normal-tension glaucoma has, however, not been paralleled by a comparable progress in the development of therapeutic modalities capable of influencing favorably ocular blood flow. Today, calcium channel blockers seem to be the most promising adjunctive treatment to be considered in patients with glaucomatous optic neuropathy without increased intraocular pressure.
Collapse
|
32
|
Fuchsjäger-Mayrl G, Wally B, Rainer G, Buehl W, Aggermann T, Kolodjaschna J, Weigert G, Polska E, Eichler HG, Vass C, Schmetterer L. Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension. Br J Ophthalmol 2005; 89:1293-7. [PMID: 16170119 PMCID: PMC1772863 DOI: 10.1136/bjo.2005.067637] [Citation(s) in RCA: 76] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND There is evidence that perfusion abnormalities of the optic nerve head are involved in the pathogenesis of glaucoma. There is therefore considerable interest in the effects of topical antiglaucoma drugs on ocular blood flow. A study was undertaken to compare the ocular haemodynamic effects of dorzolamide and timolol in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT). METHODS One hundred and forty patients with POAG or OHT were included in a controlled, randomised, double blind study in two parallel groups; 70 were randomised to receive timolol and 70 to receive dorzolamide for a period of 6 months. Subjects whose intraocular pressure (IOP) did not respond to either of the two drugs were switched to the alternative treatment after 2 weeks. Scanning laser Doppler flowmetry was used to measure blood flow in the temporal neuroretinal rim and the cup of the optic nerve head. Pulsatile choroidal blood flow was assessed using laser interferometric measurement of fundus pulsation amplitude. RESULTS Five patients did not respond to timolol and were changed to the dorzolamide group, and 18 patients changed from dorzolamide treatment to timolol. The effects of both drugs on IOP and ocular perfusion pressure were comparable. Dorzolamide, but not timolol, increased blood flow in the temporal neuroretinal rim (8.5 (1.6)%, p<0.001 versus timolol) and the cup of the optic nerve head (13.5 (2.5)%, p<0.001 versus timolol), and fundus pulsation amplitude (8.9 (1.3)%, p<0.001 versus timolol). CONCLUSIONS This study indicates augmented blood flow in the optic nerve head and choroid after 6 months of treatment with dorzolamide, but not with timolol. It remains to be established whether this effect can help to reduce visual field loss in patients with glaucoma.
Collapse
Affiliation(s)
- G Fuchsjäger-Mayrl
- Department of Clinical Pharmacology, Medical University of Vienna, Austria
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Abstract
Glaucoma is a family of diseases commonly characterised by progressive optic neuropathy with associated visual field deficits for which elevated intraocular pressure (IOP) is one of the primary risk factors. For more than a century the main goal of glaucoma management has been to eliminate the risk associated with elevated IOP. In recent years, accumulating evidence of pressure-independent causes of glaucomatous optic neuropathy has led to the recognition that lowering IOP alone may often be insufficient for the long-term preservation of visual function. An innovative therapeutic approach is now emerging to prevent progression of glaucomatous optic neuropathy and preserve vision, irrespective of disease aetiology: direct protection of the optic nerve. In addition to reducing the risk associated with elevated IOP, this neuroprotective approach will augment the overall goal of preserving the optic nerve through direct promotion of retinal ganglion cell (RGC) survival and/or prevention of RGC death. Although no currently available compounds have been clinically demonstrated to provide neuroprotective benefit in glaucoma, recent preclinical studies have shown that alpha-adrenergic agonists, such as brimonidine, provide neuroprotective benefits, as well as excellent IOP lowering efficacy. In addition, new agents with promising neuroprotective utility that are emerging from other studies are now being investigated for efficacy in glaucoma. The review discusses recently introduced compounds and new drugs in development with regard to their potential value in conventional and/or neuroprotective strategies for vision sparing in glaucoma.
Collapse
Affiliation(s)
- R David
- Allergan, 2525 Dupont Drive, PO Box 19534, Irvine, CA 92623-9534, USA
| |
Collapse
|
34
|
Stefánsson E, Pedersen DB, Jensen PK, la Cour M, Kiilgaard JF, Bang K, Eysteinsson T. Optic nerve oxygenation. Prog Retin Eye Res 2005; 24:307-32. [PMID: 15708831 DOI: 10.1016/j.preteyeres.2004.09.001] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The oxygen tension of the optic nerve is regulated by the intraocular pressure and systemic blood pressure, the resistance in the blood vessels and oxygen consumption of the tissue. The oxygen tension is autoregulated and moderate changes in intraocular pressure or blood pressure do not affect the optic nerve oxygen tension. If the intraocular pressure is increased above 40 mmHg or the ocular perfusion pressure decreased below 50 mmHg the autoregulation is overwhelmed and the optic nerve becomes hypoxic. A disturbance in oxidative metabolism in the cytochromes of the optic nerve can be seen at similar levels of perfusion pressure. The levels of perfusion pressure that lead to optic nerve hypoxia in the laboratory correspond remarkably well to the levels that increase the risk of glaucomatous optic nerve atrophy in human glaucoma patients. The risk for progressive optic nerve atrophy in human glaucoma patients is six times higher at a perfusion pressure of 30 mmHg, which corresponds to a level where the optic nerve is hypoxic in experimental animals, as compared to perfusion pressure levels above 50 mmHg where the optic nerve is normoxic. Medical intervention can affect optic nerve oxygen tension. Lowering the intraocular pressure tends to increase the optic nerve oxygen tension, even though this effect may be masked by the autoregulation when the optic nerve oxygen tension and perfusion pressure is in the normal range. Carbonic anhydrase inhibitors increase the optic nerve oxygen tension through a mechanism of vasodilatation and lowering of the intraocular pressure. Carbonic anhydrase inhibition reduces the removal of CO2 from the tissue and the CO2 accumulation induces vasodilatation resulting in increased blood flow and improved oxygen supply. This effect is inhibited by the cyclo-oxygenase inhibitor, indomethacin, which indicates that prostaglandin metabolism plays a role. Laboratory studies suggest that carbonic anhydrase inhibitors might be useful for medical treatment of optic nerve and retinal ischemia, potentially in diseases such as glaucoma and diabetic retinopathy. However, clinical trials and needed to test this hypotheses.
Collapse
Affiliation(s)
- Einar Stefánsson
- Department of Ophthalmology, University of Iceland, National University Hospital, Landspitali, 105 Reykjavík, Iceland.
| | | | | | | | | | | | | |
Collapse
|
35
|
|
36
|
Ban K, Kochi K, Imai K, Okada K, Orihashi K, Sueda T. Novel Doppler Technique to Assess Systemic Vascular Resistance The Snuffbox Technique. Circ J 2005; 69:688-94. [PMID: 15914947 DOI: 10.1253/circj.69.688] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND To explore an alternative to the systemic vascular resistance index (SVRI) for monitoring peripheral circulation in patients in the intensive care unit (ICU), the resistive index (RI) in the upper extremity arteries was measured by using surface Doppler ultrasound. METHODS AND RESULTS The correlation between RI and vascular resistance was assessed in vitro using a vessel phantom in a Donovan-type mock circulation system. In addition, 15 ICU patients who had undergone open-heart surgery were studied. Mean arterial pressure, central venous pressure and cardiac output were measured 30 times at 10 min intervals after patients returned to the ICU following surgery, and the SVRI was calculated from these parameters. At the same time points, 3 parts of the upper extremity arteries (brachial artery in the cubital fossa (BA), radial artery at the wrist (RA), and radial artery at the anatomical snuffbox (SB)) were scanned by Doppler ultrasound, and the resistance index (RI) for each artery region was calculated. In vitro, RI increased with higher vascular resistance, exhibiting a significant correlation (r = 0.982, p < 0.0001). In vivo, the average incidence angles at the BA and RA were larger than 60 degrees , while that at the SB was only 11.5+/-10.8 degrees. The overall correlation between SVRI and RI for all patients was not significant for the BA or RA, but was significant for the SB (p < 0.0001). In individual patients, the correlation of SVRI with RI at the BA or RA was significant in 3 patients only, whereas significant correlation for the SB was observed in all patients. Doppler waveform analysis at the SB revealed diastolic flow reversal with increased SVRI. CONCLUSIONS Measurement at the SB provides an ideal ultrasound incidence angle for the measurement of blood flow velocity. Hence, RI measured in this way may serve as an indicator of peripheral vascular resistance, and may be effective for the evaluation of peripheral circulatory disturbance.
Collapse
Affiliation(s)
- Koji Ban
- Department of Surgery, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.
| | | | | | | | | | | |
Collapse
|
37
|
Abstract
AIM To document the change in pattern of glaucoma treatment in Australia over the decade 1994-2003. METHODS Observational study: retrospective data audit. RESULTS The total number of prescriptions for glaucoma items has increased in this time period from 1.9 million to 3.3 million, with a cost increase to the Pharmaceutical Benefits Scheme (PBS) of in excess of 50m dollars. The largest increase has been in the class of prostaglandin analogues, which now comprise 49% of all glaucoma topical therapy prescriptions. Rates of laser trabeculoplasty and trabeculectomy surgery have fallen by 60% and 58%, respectively. Rates for secondary procedures such as repeat trabeculectomy, drainage implant devices and cycloablation have remained stable, although with some variation between Australian states. CONCLUSIONS The introduction of multiple new medications has resulted in a decline in the amount of glaucoma surgery and laser trabeculoplasty performed. There has been an associated increase in the total number of glaucoma prescription items dispensed, and a large increase in the cost to the PBS of this change. Outcome measures of the benefit of these changes are lacking.
Collapse
Affiliation(s)
- Mark J Walland
- Royal Victorian Eye and Ear Hospital and Department of Surgery, Royal Melbourne Hospital (University of Melbourne), Melbourne, Victoria, Australia.
| |
Collapse
|
38
|
Nakanishi M, Sugiyama T, Nakajima M, Ikeda T. Changes in orbital hemodynamics induced by nipradilol in healthy volunteers. J Ocul Pharmacol Ther 2004; 20:25-33. [PMID: 15006156 DOI: 10.1089/108076804772745437] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
We evaluated changes in ocular hemodynamics induced by nipradilol, an NO donor, applied as an eye drop. Eight volunteers underwent color Doppler imaging for measurement of hemodynamic parameters in the central retinal artery (CRA) and ophthalmic artery (OA) after instillation of nipradilol. Intraocular pressure (IOP) and systemic blood pressure were also measured. Two months later, the same volunteers were examined after instillation of saline into the same eyes to obtain control data. The pulsatility index in the CRA was significantly lowered in the eyes treated with nipradilol compared with control eyes. Blood velocities in the CRA, hemodynamic parameters in the OA, IOP, blood pressure, and ocular perfusion pressure were unaffected by nipradilol. The current study suggests that nipradilol may dilate the CRA as a result of reduced vascular resistance in humans.
Collapse
Affiliation(s)
- Megumi Nakanishi
- Department of Ophthalmology, Osaka Medical College, Osaka, Japan
| | | | | | | |
Collapse
|
39
|
Kiilgaard JF, Pedersen DB, Eysteinsson T, la Cour M, Bang K, Jensen PK, Stefánsson E. Optic nerve oxygen tension: the effects of timolol and dorzolamide. Br J Ophthalmol 2004; 88:276-9. [PMID: 14736791 PMCID: PMC1772002 DOI: 10.1136/bjo.2003.021857] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BACKGROUND/AIMS The authors have previously reported that carbonic anhydrase inhibitors such as acetazolamide and dorzolamide raise optic nerve oxygen tension (ONPO(2)) in pigs. The purpose of the present study was to investigate whether timolol, which belongs to another group of glaucoma drugs called beta blockers, has a similar effect. In addition, the effect of dorzolamide and timolol in combination was studied. METHODS Polarographic oxygen electrodes were placed transvitreally over the optic disc in anaesthetised pigs and ONPO(2) was recorded continually. Drugs were administered intravenously either as 100 mg timolol followed by 500 mg dorzolamide (n = 5), 500 mg dorzolamide followed by 100 mg timolol (n = 5), or 100 mg timolol and 500 mg dorzolamide given simultaneously (n = 5). Arterial blood pressure, blood gasses, and heart rate were recorded. RESULTS ONPO(2) was unaffected by administration of 100 mg timolol as an intravenous injection (n = 5). Administration of 500 mg dorzolamide by itself significantly increased ONPO(2) from 2.96 (SD 0.62) kPa to 3.69 (SD 0.88) kPa (n = 4, p = 0.035). The dorzolamide induced ONPO(2) increase was not significantly different from the ONPO(2) increases were seen when dorzolamide was administered simultaneous with (n = 5) or 35 minutes (n = 5) after 100 mg timolol. CONCLUSION Systemic administration of timolol does not affect the optic nerve oxygen tension despite its lowering effect on the intraocular pressure. Additionally, timolol does not affect the ONPO(2) increasing effect of dorzolamide.
Collapse
Affiliation(s)
- J F Kiilgaard
- Department of Ophthalmology, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen Ø, Denmark.
| | | | | | | | | | | | | |
Collapse
|
40
|
Costa VP, Harris A, Stefánsson E, Flammer J, Krieglstein GK, Orzalesi N, Heijl A, Renard JP, Serra LM. The effects of antiglaucoma and systemic medications on ocular blood flow. Prog Retin Eye Res 2004; 22:769-805. [PMID: 14575724 DOI: 10.1016/s1350-9462(03)00064-8] [Citation(s) in RCA: 102] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Based on the body of evidence implicating ocular blood flow disturbances in the pathogenesis of glaucoma, there is great interest in the investigation of the effects of antiglaucoma drugs and systemic medications on the various ocular vascular beds. The primary aim of this article was to review the current data available on the effects of antiglaucoma drugs and systemic medications on ocular blood flow. We performed a literature search in November 2002, which consisted of a textword search in MEDLINE for the years 1968-2002. The results of this review suggest that there is a severe lack of well-designed long-term studies investigating the effects of antiglaucoma and systemic medications on ocular blood flow in glaucomatous patients. However, among the 136 articles dealing with the effect of antiglaucoma drugs on ocular blood flow, only 36 (26.5%) investigated the effects of medications on glaucoma patients. Among these 36 articles, only 3 (8.3%) were long-term studies, and only 16 (44.4%) were double-masked, randomized, prospective trials. Among the 33 articles describing the effects of systemic medications on ocular blood flow, only 11 (33.3%) investigated glaucoma patients, of which only one (9.1%) was a double-masked, randomized, prospective trial. Based on this preliminary data, we would intimate that few antiglaucoma medications have the potential to directly improve ocular blood flow. Unoprostone appears to have a reproducible antiendothelin-1 effect, betaxolol may exert a calcium-channel blocker action, apraclonidine consistently leads to anterior segment vasoconstriction, and carbonic anhydrase inhibitors seem to accelerate the retinal circulation. Longitudinal, prospective, randomized trials are needed to investigate the effects of vasoactive substances with no hypotensive effect on the progression of glaucoma.
Collapse
Affiliation(s)
- Vital P Costa
- Glaucoma Service, University of Campinas, Rua Bauru, 40, São Paulo 01248-010, Brazil.
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Aydin A, Wollstein G, Price LL, Schuman JS. Evaluating pulsatile ocular blood flow analysis in normal and treated glaucomatous eyes. Am J Ophthalmol 2003; 136:448-53. [PMID: 12967797 DOI: 10.1016/s0002-9394(03)00237-x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
PURPOSE To evaluate pulsatile ocular blood flow (POBF) analysis in normal subjects and glaucoma patients by comparison of POBF measurements with functional (as determined by visual field [VF]) and structural (as determined by optical coherence tomography [OCT]) measures. DESIGN Prospective, cross-sectional study. METHODS Forty-one eyes of 24 consecutive glaucoma patients and 20 eyes of 10 healthy subjects were studied; POBF analysis was performed on all subjects at the same visit as VF testing and OCT retinal nerve fiber layer (NFL) thickness measurement. The mean results of normal and glaucomatous eyes were compared for each method. Correlation between measurements obtained with each modality and the discriminating power using receiver operator characteristic curves was tested. RESULTS The mean POBF (standard deviation [SD]) in the normal group was 1,010.4 (292.8) microl/min and 989.3 (305.5) microl/min in the glaucoma group (P =.90). Significant differences between groups were found for VF mean deviation and pattern standard deviation (P =.02, P =.004, respectively) and OCT mean NFL thickness (P <.0001). No correlation was found between POBF parameters and intraocular pressure, VF, or OCT variables except for intraocular pressure in glaucoma group (r = -.43, P =.003). The area under the receiver operator characteristic curves was higher for VF indexes and OCT mean NFL thickness than POBF parameters for distinguishing between normal and glaucomatous eyes. CONCLUSIONS The wide range of normal values and the low discriminating power of POBF between normal and glaucomatous eyes limits the clinical use of the device for glaucoma patients.
Collapse
Affiliation(s)
- Ali Aydin
- New England Eye Center, Tufts-New England Medical Center, Tufts School of Medicine, Boston, Massachusetts 02111, USA
| | | | | | | |
Collapse
|
42
|
Inan UU, Ermis SS, Yücel A, Oztürk F. The effects of latanoprost and brimonidine on blood flow velocity of the retrobulbar vessels: a 3-month clinical trial. ACTA OPHTHALMOLOGICA SCANDINAVICA 2003; 81:155-60. [PMID: 12752054 DOI: 10.1034/j.1600-0420.2003.00049.x] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVE To investigate the effects of topical latanoprost 0.005% and topical brimonidine tartrate 0.2% on retrobulbar blood flow in patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT). METHODS Forty-one consecutive patients with POAG and OHT were enrolled in this prospective, open-label, randomized, parallel study. Patients received either latanoprost 0.005% or brimonidine 0.2% for 3 months. Baseline retrobulbar blood flow measurements of the ophthalmic artery, central retinal artery and temporal short posterior ciliary artery were taken using colour Doppler imaging ultrasound, concurrently with systemic blood pressure, heart rate, ocular perfusion pressure and intraocular pressure (IOP) measurements. These measurements were repeated after 3 months. RESULTS Both latanoprost and brimonidine significantly reduced IOP (p < 0.05). While there was a statistically significant increase in peak systolic velocity of the ophthalmic artery, no significant change was observed in the other vessels with latanoprost treatment (p < 0.05). Topical brimonidine did not significantly alter flow velocities or resistive indices in the retrobulbar vessels after 3 months. CONCLUSION Topical latanoprost and brimonidine significantly reduced IOP in patients with POAG and OHT without causing significant haemodynamic alterations in the retrobulbar vessels.
Collapse
Affiliation(s)
- Umit Ubeyt Inan
- Department of Ophthalmology, Kocatepe University, School of Medicine, Afyon, Turkey.
| | | | | | | |
Collapse
|
43
|
Uji Y, Kuze M, Matubara H, Doi M, Sasoh M. Effects of the beta1-selective adrenergic antagonist betaxolol on electroretinography in the perfused cat eye. Doc Ophthalmol 2003; 106:37-41. [PMID: 12675484 DOI: 10.1023/a:1022404630736] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
The effects of the beta1-selective adrenergic antagonist betaxolol on electroretinography (ERG) were studied in the isolated and arterially perfused cat eye. Betaxolol increased the perfusion flow rate, significantly at the administrations of more than 50 microM concentrations and induced a dose-related, reversible increase in the amplitudes of both the a-wave and b-wave of ERG. These results suggest that the calcium-channel blocking mechanism of betaxolol has a beneficial influence on ocular blood flow and retinal electrical activity in response to light. As it is known that ERG is a good indicator of the functional integrity of the retina, this indicates that betaxolol could be an ideal drug for treating glaucoma in which ischemia is involved to some extent.
Collapse
Affiliation(s)
- Yukitaka Uji
- Department of Ophthalmology, Mie University School of Medicine, Edobashi 2-174, Tsu 514-8507, Japan
| | | | | | | | | |
Collapse
|
44
|
Sycha T, Vass C, Findl O, Bauer P, Groke I, Schmetterer L, Eichler H. Interventions for normal tension glaucoma. Cochrane Database Syst Rev 2003:CD002222. [PMID: 14583947 DOI: 10.1002/14651858.cd002222] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND Normal tension glaucoma is a clinical condition in which the optic nerve is pathologically excavated and the visual field is disturbed. Nevertheless it has been assumed that intraocular pressure plays a role in the progression of visual field defects in this disease, but other, mainly vascular factors, have been discussed as well. OBJECTIVES The objective of this review is to assess the effects of medical and surgical treatments for normal tension glaucoma. SEARCH STRATEGY Trials were identified from the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Group trials register), MEDLINE, EMBASE and BIOSIS Previews. Bibliographies of identified trials were searched to find additional trials. In addition, investigators and pharmaceutical companies were contacted. Date of last search: January 2001. SELECTION CRITERIA This review includes randomised controlled trials in which medical or surgical interventions were compared to no treatment, placebo or other treatment in people with normal tension glaucoma. Two reviewers independently assessed the full text copies of the possibly relevant trials. Trial quality was assessed according to the methods set out in Section 6 of the Cochrane Reviewers' Handbook (Clarke 2000). DATA COLLECTION AND ANALYSIS Data were extracted by two reviewers and results were compared for differences. Discrepancies were resolved by discussion. The heterogeneity of interventions, follow-up periods and outcomes did not allow for statistical combinations of the study results. MAIN RESULTS According to the selection criteria on visual field loss, eight studies were included in this review. Only three studies focussed on patient relevant outcomes. In one trial a beneficial effect of lowering intraocular pressure was found, but only if data were corrected for cataract development. In two small studies a beneficial effect on visual field loss of brovincamine, a calcium antagonist was reported. REVIEWER'S CONCLUSIONS In one study the effect of intraocular pressure lowering on visual field outcome was only significant when data were corrected for cataract development. The results for calcium antagonists are promising, but larger trials have to be performed. Studies that focussed on reduction of intraocular pressure or haemodynamic variables are not necessarily relevant for the outcome in people with normal tension glaucoma.
Collapse
Affiliation(s)
- T Sycha
- Department of Clinical Pharmacology, University of Vienna, Medical School, Allgemeines Krankenhaus Wien, Währinger-Gürtel 18-20, Vienna, Austria, A-1090
| | | | | | | | | | | | | |
Collapse
|
45
|
Hafez AS, Bizzarro RLG, Rivard M, Lesk MR. Changes in optic nerve head blood flow after therapeutic intraocular pressure reduction in glaucoma patients and ocular hypertensives. Ophthalmology 2003; 110:201-10. [PMID: 12511367 DOI: 10.1016/s0161-6420(02)01716-5] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
PURPOSE To detect and quantify changes in optic nerve head (ONH) and peripapillary retinal blood flow by scanning laser Doppler flowmetry (SLDF) in open-angle glaucoma (OAG) and ocular hypertension (OHT) after therapeutic intraocular pressure (IOP) reduction. DESIGN Prospective, nonrandomized, self-controlled trial. PARTICIPANTS Twenty patients with OAG and 20 patients with OHT with clinical indications for therapeutic IOP reduction were prospectively enrolled. INTERVENTION IOP reduction was achieved by medical, laser, or surgical therapy. All patients had IOP reductions more than 20% and a minimum of 4 weeks follow-up. MAIN OUTCOME MEASURES Blood flow measurements were performed by SLDF analysis software (version 3.3) using Heidelberg Retina Flowmeter images. Statistical evaluations were performed on both groups using a two-tailed distribution paired t test. RESULTS Twenty patients with OAG had a mean IOP reduction of 37% after treatment. In these patients, mean (+/- standard deviation) rim blood flow increased by 67% (from 158 +/- 79 arbitrary units to 264 +/- 127 arbitrary units, P = 0.001), whereas mean temporal peripapillary retinal flow decreased by 7.4% (P = 0.24), and mean nasal peripapillary retinal flow increased by 0.3% (P = 0.96). Twenty OHT patients had a mean IOP reduction of 33% after treatment. In contrast to the OAG group, neither the mean rim blood flow (7.5% increase from 277 +/- 158 arbitrary units to 298 +/- 140 arbitrary units, P = 0.41) nor the mean temporal (P = 0.35) or nasal (P = 0.88) peripapillary retinal flow changed significantly. CONCLUSIONS For a similar percentage of IOP reduction, OAG patients had a statistically significant improvement of blood flow in the neuroretinal rim of the ONH, whereas OHT patients did not demonstrate such a change. Peripapillary retinal blood flow, expected to be affected less in glaucoma, remained stable in both groups. In addition to indicating a response to therapy in OAG patients, the reported changes in rim perfusion suggest that ONH autoregulation may be defective in OAG while intact in OHT.
Collapse
Affiliation(s)
- Ali S Hafez
- Department of Ophthalmology and Guy-Bernier Research Center, Maisonneuve-Rosemont Hospital, University of Montreal, Montreal, Quebec, Canada
| | | | | | | |
Collapse
|
46
|
Vainio-Jylhä E, Vuori ML, Nummelin K. Progression of retinal nerve fibre layer damage in betaxolol- and timolol-treated glaucoma patients. ACTA OPHTHALMOLOGICA SCANDINAVICA 2002; 80:495-500. [PMID: 12390160 DOI: 10.1034/j.1600-0420.2002.800507.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
PURPOSE It has been suggested that there are differences between selective and non-selective beta-blocking agents in their ability to protect glaucomatous eyes. The purpose of this study was to follow glaucoma patients treated with either betaxolol 0.5% or timolol 0.25% ophthalmic solutions and to compare the rate and degree of progression in retinal nerve fibre layer (RNFL) defects between the groups. METHODS A total of 64 patients were prospectively recruited in a double-masked study and randomly divided into two treatment groups. Retinal nerve fibre layer photographs were analysed. The incidence and total amount of progression in each group were recorded. The rate of impairment was demonstrated using Kaplan Meier survival curves. RESULTS The analysis included 27 patients treated with betaxolol and 28 patients treated with timolol. Of these, 30% of betaxolol-treated patients and 46% of timolol-treated patients had RNFL damage progression (p = 0.20). The total amount or rate of progression did not differ significantly between the two groups. There was no significant difference in intraocular pressure (IOP) levels between the groups (p = 0.68) during follow-up. The degree of RNFL deterioration did not correlate to the amount of IOP reduction. CONCLUSION The group treated with betaxolol 0.5% and the group treated with timolol 0.25% did not differ significantly in RNFL damage progression.
Collapse
|
47
|
Abstract
Normal-tension glaucoma was previously thought to be pressure insensitive, as medical treatment hardly reduced intraocular pressure and it did not prevent visual field loss. In the last decade, however, evidence has shown that the treatment of normal-tension glaucoma by lowering intraocular pressure can slow the deterioration of visual fields, hence the glaucomatous process. It was shown that a reduction of IOP of at least 30% is needed to induce a favorable alteration in the course of normal-tension glaucoma. New agents, such as prostaglandin analogs, the alpha(2)-adrenoceptor agonist brimonidine, and carbonic anhydrase inhibitors, have become available and may be of use in the treatment of normal-tension glaucoma. Monotherapy with prostaglandin analogs may meet the target of a reduction of IOP with 30%, but combination therapy will be needed in many cases. Few studies have been performed with brimonidine, travoprost, and bimatoprost, and it is suggested that more attention should be given to studies with these agents, as about 30% of patients with open angles and glaucomatous visual field defects have normal-tension glaucoma. Although neuroprotection is the goal of the future, no hard data are available yet which demonstrate that treatment with these agents will indeed result in preservation of visual fields.
Collapse
Affiliation(s)
- Philip F J Hoyng
- Netherlands Ophthalmic Research Institute, Meibergdreef 47, 1105 BA Amsterdam, The Netherlands
| | | |
Collapse
|
48
|
Abstract
The published evidence that instilled drugs can affect the blood supply to the retina and optic nerve head in humans is examined. As a background, seven techniques that have been used to measure flow are briefly described and criticized. For timolol, the corresponding measurements, obtained by a number of investigators are evaluated. The outcome is very erratic and does not allow any conclusion as to the effect of this drug on flow. Consideration is then given to the possible mechanism whereby a drug could affect blood flow; directly, by diffusion to receptors on the vessels, or indirectly, through more anterior receptors. The question is raised whether the small changes in circulation induced by drugs would not be swamped by those resulting from natural alterations in the ambient light level. The literature was analyzed in the hope of identifying discrete entry pathways, for example, through the lens or the suprachoroidal space, that are sufficiently permeable to allow a significant quantity of drug to pass. There was an indication that a drug might diffuse through the lens cortex in sufficient quantity to cause a measurable rise in its concentration in the vitreous. In general, however, there was insufficient quantitative data to allow any meaningful predictions to be made. Stimulated by recent evidence, it is suggested that drug penetration from the tear fluid takes place by direct diffusion across the conjunctiva into the sclera and orbit when the head is supine.
Collapse
Affiliation(s)
- David M Maurice
- Department of Ophthalmology, Columbia University, 630 West 168th Street, New York, NY 10032, USA.
| |
Collapse
|
49
|
Steigerwalt RD, Laurora G, Belcaro GV, Cesarone MR, De Sanctis MT, Incandela L, Minicucci R. Ocular and retrobulbar blood flow in ocular hypertensives treated with topical timolol, betaxolol and carteolol. J Ocul Pharmacol Ther 2001; 17:537-44. [PMID: 11777177 DOI: 10.1089/10807680152729220] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The purpose of this study was to evaluate the effect of topical timolol 0.5%, betaxolol 0.5% and carteolol 2% on the blood flow velocity of the central retinal artery (CRA), the posterior ciliary artery (PCA) and the ophthalmic artery (OA) in patients with ocular hypertension. A group of 14 patients with ocular hypertension and a group of 11 normals were studied. The color Doppler was used to measure the peak systolic flow velocity (PSFV) and the end diastolic flow velocity (EDFV) of the CRA, the PCA and the OA in the normals and in the patients. The normals were under no treatment, while the patients were studied before and after treatment with topical timolol 0.5%, betaxolol 0.5% and carteolol 2%. In the systolic phase, there was a significant increase in the flow velocity of the CRA with all three drugs. In the diastolic phase of the CRA, the increase was significant for timolol 0.5% and carteolol 2% but not for betaxolol 0.5%. The flow velocity of the PCA and OA remained unchanged. In this study of 14 patients with ocular hypertension, topical timolol 0.5%, betaxolol 0.5% and carteolol 2% led to a significant increase in the flow velocity of the CRA without creating a steal or decrease in the flow velocity of the PCA.
Collapse
Affiliation(s)
- R D Steigerwalt
- Angiology and Vascular Surgery Center, San Valentino, Pescara, Italy.
| | | | | | | | | | | | | |
Collapse
|
50
|
Bergstrand IC, Heijl A, Wollmer P, Hansen F, Harris A. Timolol increased retrobulbar flow velocities in untreated glaucoma eyes but not in ocular hypertension. ACTA OPHTHALMOLOGICA SCANDINAVICA 2001; 79:455-61. [PMID: 11594978 DOI: 10.1034/j.1600-0420.2001.790505.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
PURPOSE To investigate retrobulbar blood flow velocities and the effects of topical timolol treatment in eyes with newly detected, previously untreated open angle glaucoma or ocular hypertension. METHODS Fifteen eyes with open angle glaucoma (OAG) and 12 eyes with ocular hypertension (OH), in the same number of patients, all untreated and newly detected, were examined with colour Doppler imaging of retrobulbar vessels before and after 1 month of topical timolol treatment (0.5% Timoptic BID). RESULTS Baseline central retinal artery end diastolic velocity was lower (48%, p=0.0002) and resistive index higher (7.6%, p=0.018) in the OAG group than in the OH group. In the glaucoma group mean end diastolic velocity increased by 41%, (p=0.006) while resistive index decreased by 5.8%, (p=0.02) on treatment, while no significant changes were seen in the OH group. Blood flow velocities in the ophthalmic artery did not change with treatment. Baseline IOP and IOP reduction did not differ between OAG and OH group. CONCLUSION Peripheral resistance to blood flow was found to be increased in untreated glaucoma eyes as compared to a similar group of eyes with ocular hypertension. Timolol treatment diminished resistance significantly in the glaucoma group, but not in the ocular hypertension group. Thus the two groups responded differently to timolol treatment. The reaction to IOP lowering treatment could indicate defective autoregulation in the glaucoma group.
Collapse
Affiliation(s)
- I C Bergstrand
- Department of Ophthalmology, Malmö University Hospital, Malmö, Sweden.
| | | | | | | | | |
Collapse
|